Atai Life Sciences N.V. (ATAI)

$4.48 -0.80 (-15.15%)
Market Cap 1.25B
Revenue (ttm) 310,000.00
Net Income (ttm) -149.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -48,151.61%
Debt to Equity Ratio 0.00
Volume 10,284,041
Avg Vol 5,985,524
Day's Range N/A - N/A
Shares Out 233.78M
Stochastic %K 10%
Beta 1.59
Analysts Strong Sell
Price Target $12.12

Company Profile

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial...

Industry: Biotechnology
Sector: Healthcare
Phone: 332 282 0507
Address:
250 West 34th Street, New York, United States
GeorgeJetson17
GeorgeJetson17 Feb. 6 at 10:31 PM
$ATAI I feel like ATAI’s last dip was caused by Bitcoin. The two shouldn’t be correlated, but it was more about retail investors selling riskier assets. Thanks for attending my TedTalk.
1 · Reply
Tifosi007
Tifosi007 Feb. 6 at 10:15 PM
$ATAI $ATAI Looks like they had to crash it one last time to take it back to 4+ which is all done now..
0 · Reply
matrixtrade123
matrixtrade123 Feb. 6 at 8:31 PM
$ATAI back over the 200 dma only under for a quick 2 days __ lets ROCK back OVER the 100 & 50 ma because I WANT TO ROCK ~!
0 · Reply
Luvstocks26
Luvstocks26 Feb. 6 at 8:07 PM
$ATAI
1 · Reply
Luvstocks26
Luvstocks26 Feb. 6 at 7:54 PM
$ATAI
0 · Reply
wmoller
wmoller Feb. 6 at 7:43 PM
$ATAI Just can't keep a future 10B-20B+ dollar market cap company down...starting to get excited for the EMP-01 phase 2 data...only 7 weeks left in Q1...GLTA!
1 · Reply
stoxx0007
stoxx0007 Feb. 6 at 7:43 PM
$ATAI =... there's nothing to see 👀 here.... keep it moving 🤘
0 · Reply
canuck_trader92
canuck_trader92 Feb. 6 at 5:47 PM
$ATAI Nice dip to buy in here👀
0 · Reply
Ahmedpop
Ahmedpop Feb. 6 at 5:19 PM
$ATAI
0 · Reply
JasonCO
JasonCO Feb. 6 at 5:14 PM
$ATAI nice day
0 · Reply
Latest News on ATAI
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation

Jan 16, 2026, 7:00 AM EST - 22 days ago

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

Jan 8, 2026, 7:00 AM EST - 4 weeks ago

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

Dec 23, 2025, 7:00 AM EST - 6 weeks ago

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

Enhanced Fortifies Executive Leadership Team & Board of Directors

Nov 19, 2025, 7:32 PM EST - 2 months ago

Enhanced Fortifies Executive Leadership Team & Board of Directors

Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression Transcript

Nov 11, 2025, 9:21 AM EST - 3 months ago

Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression Transcript

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

Oct 20, 2025, 5:29 PM EDT - 3 months ago

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

Atai Life Sciences And Beckley Psytech: Promising Emerging Leader In Psychedelics

Oct 20, 2025, 9:00 AM EDT - 3 months ago

Atai Life Sciences And Beckley Psytech: Promising Emerging Leader In Psychedelics

atai Life Sciences Announces Pricing of Public Offering of Common Shares

Oct 16, 2025, 10:31 PM EDT - 4 months ago

atai Life Sciences Announces Pricing of Public Offering of Common Shares

atai Life Sciences Announces Proposed Public Offering of Common Shares

Oct 16, 2025, 4:12 PM EDT - 4 months ago

atai Life Sciences Announces Proposed Public Offering of Common Shares

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

Oct 16, 2025, 4:10 PM EDT - 4 months ago

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside

Oct 13, 2025, 2:21 PM EDT - 4 months ago

Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside

Atai Life Sciences: Still A Decent Prospect - But Only Just

Oct 1, 2025, 2:40 PM EDT - 4 months ago

Atai Life Sciences: Still A Decent Prospect - But Only Just

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients

Sep 23, 2025, 2:50 PM EDT - 4 months ago

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

Sep 23, 2025, 7:00 AM EDT - 4 months ago

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

Atai Life Sciences N.V. (ATAI) Presents at H.C.

Sep 9, 2025, 6:59 AM EDT - 5 months ago

Atai Life Sciences N.V. (ATAI) Presents at H.C.

atai Life Sciences to Participate in September Investor Conferences

Aug 28, 2025, 4:05 PM EDT - 5 months ago

atai Life Sciences to Participate in September Investor Conferences

Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus

Jul 28, 2025, 5:01 PM EDT - 6 months ago

Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

Jul 28, 2025, 10:58 AM EDT - 6 months ago

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Jul 28, 2025, 8:13 AM EDT - 6 months ago

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

RVTY

Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial

Jul 25, 2025, 4:16 PM EDT - 7 months ago

Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Jul 25, 2025, 4:05 PM EDT - 7 months ago

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD

Jul 2, 2025, 2:29 PM EDT - 7 months ago

Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

Jul 1, 2025, 9:28 AM EDT - 7 months ago

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

atai Life Sciences Announces $50 Million Private Placement Financing

Jul 1, 2025, 6:05 AM EDT - 7 months ago

atai Life Sciences Announces $50 Million Private Placement Financing

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

Jul 1, 2025, 6:00 AM EDT - 7 months ago

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

Jun 2, 2025, 6:00 AM EDT - 8 months ago

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

atai Life Sciences to Participate in Upcoming Investor Conferences

May 29, 2025, 8:30 AM EDT - 9 months ago

atai Life Sciences to Participate in Upcoming Investor Conferences

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

May 20, 2025, 7:00 AM EDT - 9 months ago

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 14, 2025, 7:00 AM EDT - 9 months ago

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

May 13, 2025, 7:01 AM EDT - 9 months ago

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

Mar 11, 2025, 7:00 AM EDT - 11 months ago

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

Atai: Following The Path That Spravato Laid And Moving Beyond It

Feb 27, 2025, 12:45 PM EST - 1 year ago

Atai: Following The Path That Spravato Laid And Moving Beyond It

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 4:10 PM EST - 1 year ago

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

Jan 29, 2025, 11:57 AM EST - 1 year ago

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

Jan 10, 2025, 7:00 AM EST - 1 year ago

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG

Oct 2, 2024, 9:21 AM EDT - 1 year ago

IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Psychedelic Stock Deep Dive: Atai Life Sciences

Sep 3, 2024, 2:00 PM EDT - 1 year ago

Psychedelic Stock Deep Dive: Atai Life Sciences

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 13, 2024, 7:10 AM EDT - 1 year ago

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

Aug 12, 2024, 12:12 PM EDT - 1 year ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

CMPS DFTX

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

Aug 7, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

Jun 26, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

Jun 20, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

May 31, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

May 15, 2024, 6:59 AM EDT - 1 year ago

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

Apr 24, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Apr 17, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

Mar 28, 2024, 7:00 AM EDT - 2 years ago

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

Mar 27, 2024, 7:00 AM EDT - 2 years ago

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

GeorgeJetson17
GeorgeJetson17 Feb. 6 at 10:31 PM
$ATAI I feel like ATAI’s last dip was caused by Bitcoin. The two shouldn’t be correlated, but it was more about retail investors selling riskier assets. Thanks for attending my TedTalk.
1 · Reply
Tifosi007
Tifosi007 Feb. 6 at 10:15 PM
$ATAI $ATAI Looks like they had to crash it one last time to take it back to 4+ which is all done now..
0 · Reply
matrixtrade123
matrixtrade123 Feb. 6 at 8:31 PM
$ATAI back over the 200 dma only under for a quick 2 days __ lets ROCK back OVER the 100 & 50 ma because I WANT TO ROCK ~!
0 · Reply
Luvstocks26
Luvstocks26 Feb. 6 at 8:07 PM
$ATAI
1 · Reply
Luvstocks26
Luvstocks26 Feb. 6 at 7:54 PM
$ATAI
0 · Reply
wmoller
wmoller Feb. 6 at 7:43 PM
$ATAI Just can't keep a future 10B-20B+ dollar market cap company down...starting to get excited for the EMP-01 phase 2 data...only 7 weeks left in Q1...GLTA!
1 · Reply
stoxx0007
stoxx0007 Feb. 6 at 7:43 PM
$ATAI =... there's nothing to see 👀 here.... keep it moving 🤘
0 · Reply
canuck_trader92
canuck_trader92 Feb. 6 at 5:47 PM
$ATAI Nice dip to buy in here👀
0 · Reply
Ahmedpop
Ahmedpop Feb. 6 at 5:19 PM
$ATAI
0 · Reply
JasonCO
JasonCO Feb. 6 at 5:14 PM
$ATAI nice day
0 · Reply
GeorgeJetson17
GeorgeJetson17 Feb. 6 at 4:55 PM
$ATAI I beat that dip like it owes me money! So glad I added more (even though I said I was done like 10,000 shares ago).
1 · Reply
Luvstocks26
Luvstocks26 Feb. 6 at 4:22 PM
$ADAPY dogshit, come to $ATAI
0 · Reply
matrixtrade123
matrixtrade123 Feb. 6 at 4:16 PM
$ATAI I do not know about you but very satisfied with today's price action __ need the P3 Start-Up Announcement like $5+ would be Nice !
1 · Reply
Jaashh
Jaashh Feb. 6 at 4:08 PM
$ATAI $ARKG When's Cathy going to double down?
1 · Reply
FLNY
FLNY Feb. 6 at 3:56 PM
$ATAI
0 · Reply
Loweryy
Loweryy Feb. 6 at 3:03 PM
$ATAI Seems like the advantages are there when comparing these guys to their comps (unless im faded). Now they just need to get through trials? am I on the right track lol?
0 · Reply
JJPick
JJPick Feb. 6 at 3:02 PM
$ATAI good recovery
0 · Reply
PrimePorter
PrimePorter Feb. 6 at 3:02 PM
$ATAI my whole watchlist is green today
0 · Reply
Nolder
Nolder Feb. 6 at 3:02 PM
$ATAI Things we love to see on a friday
0 · Reply
Nolder
Nolder Feb. 6 at 3:02 PM
$ATAI Market rebounding
0 · Reply
RandomlySelected
RandomlySelected Feb. 6 at 3:02 PM
$ATAI
0 · Reply
WeTheNorth1234
WeTheNorth1234 Feb. 6 at 2:39 PM
$ATAI Feels like catalysts are lined up
0 · Reply